Entero Therapeutics to reverse-merge with Journey Therapeutics, issuing 99% equity

GridAI Technologies Corp.

Entero (ENTO) signs binding term sheet to acquire all Journey equity; Journey holders get 99% of combined company.
Post-close, Journey CEO Henry Ji to become CEO and Chairman of the combined company.
Conditions include $5M equity financing, S-4 effectiveness, Nasdaq listing, and ENTO stockholder approval.
Combined entity will focus on Journey's NIC platform for oncology and Entero's GI pipeline (latiglutenase, adrulipase, capeserod).
NIC platform licensed from Mayo Clinic; early Phase 1 data in ovarian/endometrial cancer and non-Hodgkin's lymphoma.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.